PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9137982

Malignancy and the skeleton.

G R Mundy
View original source ↗Export metadata ↓

Abstract

Bone is one of the three most common sites of tumor metastasis. Bone metastasis is a catastrophic complication of cancer, since it is not only associated with intractable pain, but also with other morbidity such as hypercalcemia which usually hastens an uncomfortable death. Despite the importance of bone metastasis/hypercalcemia, until recently clinicians have used specific therapies only for the treatment of hypercalcemia but not for bone metastasis. During this presentation, I will review our current understanding of some of the steps involved in the pathophysiology of bone metastasis and its association with hypercalcemia, and how I think these complications of cancer should be treated.

Explore related subjects

Bone NeoplasmsHumansHypercalcemiaKidneyOsteolysisJournal ArticleResearch Support, U.S. Gov't, P.H.S.Review

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G R Mundy. 1997. Malignancy and the skeleton.. https://doi.org/10.1055/s-2007-979004

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Solitary enchondroma with clonal chromosomal abnormalities.

We report a case of a solitary enchondroma located in the head of the left fibula in a 50-year-old patient and present the findings of histopathologic investigation and cytogenetic analysis. The tumor revealed simple karyotypic abnormalities with t(8;17)(q23;p13) and loss of chromosomes 9, 19, and 22 as clonal chromosomal changes. Only a few enchondromas with chromosome aberrations have been published previously; nevertheless, it appears that benign and malignant cartilaginous tumors may have similar chromosomal abnormalities.

Bone Neoplasms↗
PubMed1998

Cytogenetic analysis of a scapular chondromyxoid fibroma.

Chondromyxoid fibroma (CMF) is a rare cartilaginous tumor of bone. It typically presents in the lower extremities of young males. Cytogenetic analysis of two chondromyxoid fibromas has been previously reported. We studied a scapular CMF from an 11-year-old female by cytogenetic and molecular cytogenetic methods and found an unbalanced reciprocal translocation between the short arm of chromosome 3 and the long arm of chromosome 6. In this translocation, several bands from chromosome 3 (3p12, 3p13, 3p14, 3p21) are lost and several bands on chromosome 6 (6q21, 6q22, 6q23) appear rearranged. Two known cartilage-related genes are located in the regions affected by this unbalanced rearrangement: the type X collagen gene (COL10A1) located at 6q21-q22 and the parathyroid hormone/parathyroid hormone-related peptide receptor gene (PTH/PTHrP) located at 3p21.1-p22. These genes function to control growth and maturation of endochondral bone, the site of origin of cartilaginous tumors.

Bone Neoplasms↗
PubMed1998

The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology.

BACKGROUND: In the United States, at least half of the patients who are irradiated are done so with palliative intent. The most common presentation is the patient with bone metastasis. However, because current scientific outcome and technology techniques are insufficient for the creation of guidelines, the American College of Radiology created a work group of experts to formulate appropriateness criteria for the irradiation of bone metastasis. METHOD: A MEDLINE search to help review the community practices was initiated. Twenty-five clinical vignettes were reviewed by a panel of experts. Recommendations for each vignette were prioritized and selected based on choices proposed by panel members. RESULT: Doses in the range of 20 Gy in 5 fractions, 30 Gy in 10 fractions, or 35 Gy in 14 fractions are acceptable in most circumstances. Daily doses > 4.0 Gy were not commonly suggested. CIRCUMSTANCES: To determine optimal dose fractionation schemes, more emphasis needs to be put on the life expectancy of the patients. Rapid schedules are acceptable in patients with short life expectancy (i.e., < 3 months), but this hypothesis needs to be tested. Further research to better define the clinical indications of hemibody irradiation and strontium-89 is recommended.

Bone Neoplasms↗